Exploring the pathogenesis and clinical implications of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO): a narrative review
Issued Date
2025-01-01
Resource Type
eISSN
2296858X
Scopus ID
2-s2.0-105004223012
Journal Title
Frontiers in Medicine
Volume
12
Rights Holder(s)
SCOPUS
Bibliographic Citation
Frontiers in Medicine Vol.12 (2025)
Suggested Citation
Simmalee K., Kawamatawong T., Vitte J., Demoly P., Lumjiaktase P. Exploring the pathogenesis and clinical implications of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO): a narrative review. Frontiers in Medicine Vol.12 (2025). doi:10.3389/fmed.2025.1514846 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/110049
Title
Exploring the pathogenesis and clinical implications of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO): a narrative review
Corresponding Author(s)
Other Contributor(s)
Abstract
The complexity and diversity of the immune response in patients with asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap present significant challenges for disease management. Relying on a limited number of biomarkers and clinical data is insufficient to fully reveal the immunopathogenesis of these diseases. However, in vitro technologies such as cell analysis, cytokine investigation, and nucleic acid sequencing have provided new insights into the underlying mechanisms of these diseases, leading to the discovery of several biomarkers—including cell degranulation, cell function, secreted cytokines, and single nucleotide polymorphisms—that have potential clinical implications. This paper reviews the immunopathogenesis in asthma, chronic obstructive pulmonary disease, and asthma-COPD overlap and examines the applications of recent in vitro models to detect candidate biomarkers that could enhance diagnostic precision, predict severity, monitor treatments, and develop new treatment strategies. A deeper understanding of the immune response in these diseases, along with the integration of in vitro models into clinical practice, could greatly improve the management of these respiratory diseases, making approaches more personalized and efficient.